https://www.selleckchem.com/pr....oducts/pacritinib-sb
Mutational profile changes from diagnostic biopsy to residual BC were a negative prognostic factor in term of relapse free survival recurrence probability in different gene profile sub-group was 42% vs 0% in the same profile one (P = .019). Conclusions Treatment selective pressure on tumor cells due to NACT changed the gene mutational profile in more than half of BC patient with residual tumor disease. Treatment-induced gene mutations significantly increase the risk of relapse. Profiling primary and residual BC is a major step
Like
Comment
Share
